FDA grants priority review to J&J heart drug
RARITAN, N.J. — The Food and Drug Administration has given priority review to a regulatory application from Johnson & Johnson for a drug designed to reduce the risk of complications from internal blood clots.
J&J’s Janssen Research & Development division announced that the FDA had given the designation to Xarelto (rivaroxaban), an oral anticoagulant, to reduce the risk of certain types of heart attacks in patients with acute coronary syndrome, which 1.2 million Americans are diagnosed with every year.
The agency gives priority review to medicines that represent advances in care or provide a treatment where no adequate therapy exists, J&J said. The designation allows the FDA to finish reviewing an application for a drug in six months rather than the usual 10.
SoloHealth appoints chief revenue officer
ATLANTA — A consumer-driven healthcare technology company has expanded its executive team to include a newly created position.
SoloHealth on Tuesday announced the appointment of Mike Griffin as its chief revenue officer, effective immediately. In his new role, Griffin will lead the company’s long-term revenue generation and oversee the strategic direction of sales and marketing. Prior to joining SoloHealth, Griffin served as EVP marketing and strategic development at EyeWonder, a provider of interactive digital advertising products.
The announcement comes as SoloHealth prepares for a national wide rollout of the SoloHealth Station, the company’s next-generation, consumer health screening kiosk.
"We are thrilled to have someone with Mike’s knowledge and strategic leadership experience join SoloHealth, especially as we ready ourselves for what promises to be a fast-growing and pivotal next 12 to 18 months for the company," SoloHealth founder and CEO Bart Foster said. "With Mike’s vast experience across numerous industries, as well as expertise in today’s digital advertising space and technologies, I’m confident that we will meet and succeed the lofty goals we’ve set for the company and the SoloHealth Station."
New PSA for Safeguard My Meds campaign features NCPA president, Oklahoma City mayor
ALEXANDRIA, Va. — In an effort to encourage the safe storage and proper disposal of prescription medicines, a campaign supported by the National Community Pharmacists Association has launched a public service announcement aimed at Oklahoma City residents.
The Safeguard My Meds campaign, which seeks to address prescription medication abuse among Americans, will launch a PSA that will air on broadcast television, radio stations and cable channels in the Oklahoma City metro area, as well as in the Daily Oklahoman, and will feature NCPA president and Oklahoma City pharmacist Lonny Wilson, along with Oklahoma City mayor Mick Cornett.
“It is time for all of us to call attention to this problem and work together to curb the abuse of prescription medications,” Wilson said. “The first place to begin is right at home. People can help keep medicines out of the wrong hands by monitoring the contents of their medicine cabinet. They should also encourage friends and relatives to safeguard medications in their homes and consult their community pharmacist about how to properly dispose of medications that are no longer needed.
“It is very important to remember that prescription medications have a legitimate medical purpose and can be very beneficial when used properly under the doctor’s supervision,” Wilson added. “The abuse of prescription medications can make it difficult for people who need these medicines to get the treatment they deserve.”
In addition to NCPA, the Safeguard My Meds campaign is supported by the U.S. Conference of Mayors and pharmaceutical company Purdue Pharma.